A mobile health intervention in HIV primary care: supporting patients at risk for ART non-adherence.
Adult
Aged
Aged, 80 and over
Anti-Retroviral Agents
/ therapeutic use
Female
HIV Infections
/ drug therapy
Humans
Male
Medication Adherence
Middle Aged
Mobile Applications
Pilot Projects
Prospective Studies
Smartphone
Telemedicine
/ methods
Treatment Adherence and Compliance
Viral Load
/ drug effects
Young Adult
ART adherence
eHealth intervention
smartphone app
viral load suppression
Journal
HIV research & clinical practice
ISSN: 2578-7470
Titre abrégé: HIV Res Clin Pract
Pays: England
ID NLM: 101738312
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
29
12
2020
medline:
20
8
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
Mobile health (mHealth) interventions that are integrated in HIV clinical settings to facilitate ongoing patient-provider communication between primary care visits are garnering evidence for their potential in improving HIV outcomes. Rango is an mHealth intervention to support engagement in HIV care and treatment adherence. This study used a single-arm prospective design with baseline and 6-month assessments for pre-post comparisons, as well as a matched patient sample for between-group comparisons to test Rango's preliminary efficacy in increasing viral suppression. The Rango sample (n = 406) was predominantly 50 years of age or older (63%; M = 50.67; SD = 10.97, 23-82), Black/African-American (44%) or Hispanic/Latinx (38%), and male (59%). At baseline, 18% reported missing at least one dose of ART in the prior three days and chart reviews of recent VL showed that nearly 82% of participants were virally suppressed. Overall 95% of the patients enrolled in Rango returned for a medical follow-up visit. Of the 65 unsuppressed patients at baseline who returned for a medical visit, 38 (59%) achieved viral suppression and only 5% of the suppressed group at baseline had an increase in viral load at 6 months despite being at risk for ART non-adherence. While viral suppression was similar between Rango participants and patients receiving treatment as usual over the same time period, it is unknown whether those patients were similarly at risk for non-adherence. Our findings support efforts to formally test this innovative approach in addressing ART non-adherence and viral suppression particularly to reach HIV treatment goals.
Identifiants
pubmed: 33369547
doi: 10.1080/25787489.2020.1862972
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM